Tricyclic mGluR1 Antagonists for Selective Pain Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for chronic pain, particularly those targeting glutamate receptors, often have significant side effects due to their impact on normal excitatory synaptic transmission, making them inadequate for long-term use.
Innovation Solution
Development of novel tricyclic compounds as selective metabotropic glutamate receptor 1 (mGluR1) antagonists to modulate pathologically abnormal spinal NMDA receptor activation associated with persistent pain states without affecting normal spinal synaptic processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NMDA receptor antagonists are used to treat chronic pain, then pain relief is achieved, but significant side effects occur due to impact on normal excitatory synaptic transmission
Solution Approach 1:
The patent applies local quality by designing mGluR1 antagonists that selectively target specific receptor subtypes (mGluR1) involved in pain pathways while sparing other glutamate receptors (NMDA, AMPA, kainate) that mediate normal synaptic transmission. This subtype-selective approach allows pain relief without the widespread excitatory transmission blockade that causes NMDA antagonist side effects
Solution Approach 2:
The patent segments the glutamate receptor system into distinct functional categories: mGluR1 for pain modulation and other glutamate receptors for normal synaptic function. By developing compounds that specifically antagonize only mGluR1, the invention separates the therapeutic effect (pain relief) from the harmful effect (disruption of normal transmission) that occurs with broad-spectrum NMDA antagonists
2Object-affected harmful factors
If selective mGluR1 antagonists are developed, then side effect liability is reduced, but drug development complexity increases
Solution Approach 1:
The patent employs parameter changes by systematically modifying molecular structures to achieve selective mGluR1 antagonism. The compounds feature specific structural parameters including a tricyclic core with particular ring configurations, substituent positions, and stereochemical features that confer mGluR1 selectivity. These parameter optimizations enable selective targeting while managing development complexity through structured molecular design
Data Source
AI summary
In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1-R4 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluRI ) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.